Health and Human Services employees were told in March to remove nicknames from email systems and signatures to comply with ...

The FDA approved nipocalimab (Imaavy) injection to treat adults and children ages 12 and older with generalized myasthenia ...

The U.S. Food and Drug Administration has approved Johnson & Johnson's drug to treat patients aged 12 years and older with an ...

British animal genetics company Genus on Wednesday said the U.S. Food and Drug Administration (FDA) approved its PRP gene ...

Multiple current and laid-off FDA employees said the abrupt layoffs had resulted in delays and disruptions to the agency's ...

The drug cytisinicline could help expand options for quitting smoking, and if approved by the FDA, would be the first new ...

The FDA has approved a monoclonal antibody to treat individuals aged 12 years and older with generalized myasthenia gravis ...

Zevaskyn is the first and only autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa ...

There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from ...

The company has predicted that Imaavy — now approved for generalized myasthenia gravis — could eventually earn more than $5 ...

The head of the Food and Drug Administration said Tuesday that the agency is now looking at whether it will still approve COVID-19 vaccines for next winter, citing a lack of data on booster shots.

The FDA doesn’t plan to execute a reorganization of the agency but will consolidate offices that handle travel, technology, ...